The role of PUVA in the treatment of psoriasis: Photobiology issues related to skin cancer incidence

American Journal of Clinical Dermatology

Volumn 1, Issue 6, 2000, Pages 337-348

  Gasparro, Francis P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; PSORALEN DERIVATIVE;

ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; METHODOLOGY; MOUSE; POINT MUTATION; PSORIASIS; PUVA; REVIEW; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DERMATOLOGIC AGENTS; GENES, P53; HUMANS; MICE; POINT MUTATION; PSORALENS; PSORIASIS; PUVA THERAPY; SKIN NEOPLASMS;

EID: 0034329455     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001060-00002     Document Type: Article

References (68)

1. Fitzpatrick TB, Pathank MA. Research and development of oral psoralen and longwave radiation photochemotherapy: 2000 B.C.-1982 A.D. Natl Cancer Inst Monogr 1984; 66: 3-11
2. El Mofty AM. A preliminary clinical report on the treatment of leukoderma with Ammi majus linn. JR Egypt Med Assn 1948; 31: 651-65
3. Bethea D, Fullmer B, Syed S, et al. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J Dermatol Sci 1999; 19: 78-88
4. Peritz AE, Gasparro FP. Psoriasis, PUVA and skin cancer - molecular epidemiology: the curious question of T→A transversions. J Investig Dermatol Symp Proc 1999; 4: 11-6
5. Morison WL, Baughman SD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134: 595-8
6. Halpern SM. Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 2000; 142: 22-31
7. Koo JY. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol 1999; 26: 723-33
8. Karasek MA. Progress in our understanding of the biology of psoriasis. Cutis 1999; 64: 319-22
9. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 133: 1104-10
10. Honigsmann H, Fitzpatrick TB, Pathak MA, et al. Oral photochemotherapy with psoralen and UVA (PUVA): principles and practice. In: Fitzpatrick TB, Eisen AZ, Wolf K, editors. Dermatology in general medicine. New York: McGraw-Hill, 1987; 1728-54
11. Parrish JA, Fitzpatrick TB, Tannenbaum L, et al. Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. N Engl J Med 1974; 291: 1207-11
12. Edelson RL, Berger CL, Gasparro FP, et al. Treatment of cutaneous T cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297-303
13. Moor ACE, FP Gasparro. Biochemical aspects of psoralen photochemotherapy. Clin Dermatol 1996; 4: 353-6
14. Musajo L, Rodighiero G, Breccia A, et al. The photoreactions between DNA and the skin-photosensitizing furocoumarin studied using labeled bergapten. Experientia 1968; 22: 75-8
15. Boyer V, Moustacchi E, Sage E. Sequence specificity in photoreaction of various psoralen derivatives with DNA: role in biological activity. Biochemistry 1988: 19: 3011-8
16. Yun MH, Choi SJ, Shim SC. A novel photoadduct of 4,5′,8-trimethylpsoralen and adenosine. Photochem Photobiol 1992; 55: 457-60
17. Liu Z, Lu Y, Lebwohl M, et al. PUVA (8-methoxypsoralen plus ultraviolet A) induces the formation of 8-hydroxy-2′-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Rad Biol Med 1999; 27: 127-33
18. Kreutzer DA, Essigmann JM. Oxidized, deaminated cytosines are a source of C→T transitions in vivo. Proc Natl Acad Sci USA 1998; 95: 3578-82
19. Frederiksen S, Hearst JE. Binding of 4′-aminomethyl-4,5′,8-trimethylpsoralen to DNA, RNA and protein in HeLa cells and Drosophila cells. Biochem Biophys Acta 1979; 563: 343-55
20. Johnson R, Staiano-Coico L, Austin L, et al. PUVA treatment selectively induces a cell cycle block and subsequent, apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63: 566-71
21. Vallat VP, Gilleaudeau P, Battat L. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283-96
22. Strauss GH, Albertini RJ, Krusinski PA, et al. 6-Thioguanine resistant peripheral blood lymphocytes in human s following psoralen, long-wave ultraviolet light (PUVA) therapy. J Invest Dermatol 1979; 73: 211-6
23. Sage E, Bredberg A. Damage distribution and mutation spectrum: the case of 8-methoxy-psoralen and UVA in mammalian cells. Mutat Res 1991; 263: 217-22
24. Yang SC, Lin JG, Chiou CC, et al. Mutation specificity of 8-methoxypsoralen plus two doses of UVA irradiation in the hprt gene in diploid human fibroblasts. Carcinogenesis 1994; 15: 201-7
25. Bredberg A, Nachmansson N. Psoralen adducts in a shuttle vector plasmid propagated in primate cells: high mutagenicity of DNA cross-links. Carcinogenesis 1987; 8: 1923-7
26. Gunther EJ, Yeasky TM, Gasparro FP, et al. Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by monoadducts as well as cross-links. Cancer Res 1995; 55: 1283-8
27. Lindelof B, Sigurgeirsson B. PUVA and cancer: a case-control study. Br J Dermatol 1993; 129: 39-41
28. Stern RS, Laird N, Melski J, et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156-61
29. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759-64
30. Stern RS, Liebman EJ, Väkevä L, et al. Oral psoralen and ultraviolet A (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998; 90: 1278-84
31. Studniberg HM, Weller P. PUVA, UVB, psoriasis and nonmelanoma cancer. J Am Acad Dermatol 1993; 29: 1013-22
32. Tokura Y, Edelson RL, Gasparro FP. Formation and removal of 8-MOP-DNA photoadducts in keratinocytes: effects of calcium concentration and retinoids. J Invest Dermatol 1991; 96: 942-9
33. Burger PM, Simons JWIM. Mutagenicity of 8-methoxypsoralen and long-wave ultraviolet irradiation in haploid human skin fibroblasts: an improved risk estimate in photochemotherapy. Mutat Res 1979; 63: 371-80
34. Stern RS, Nichols KT, Vakeva LH, et al. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336: 1041-5
35. Hannuksela-Svahn A, Pukkala E, Koulu L, et al. Cancer incidence among finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol 1999; 40: 694-6
36. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-12
37. Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587-90
38. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999; 141: 497-501
39. Donath P, Bethea D, Amici L, et al. Low and irreproducible methoxsalen levels in patients receiving photochemotherapy. Arch Dermatol 1999; 135: 604-6
40. Shephard SE, Panizzon RG. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. Dermatol 1999; 199: 106-12
41. Guo Z, Okamoto H, Danno K, et al. The effects of non-interval PUVA treatment on Langerhans cells and contact hypersensitivity. J Dermatol Sci 1992; 3: 91-6
42. Nataraj AJ, Black HS, Ananthswamy HN. Signature p53 mutations at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci USA 1996; 93: 7961-5
43. Wang XM, McNiff JM, Klump V, et al. An unexpected spectrum of p53 mutations from squamous cell carcinomas in patients treated with PUVA. Photochem Photobiol 1997; 66: 294-9
44. Nataraj AJ, Wolf P, Cerroni L, et al. P53 mutations in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA): relative frequency of PUVA-versus UV-signature mutations. J Invest Dermatol 1997; 109: 238-43
45. Sagher D, Strauss B. Insertion of nucleotides opposite apurine/apyrmidinic sites in deoxyribonucleic acid during in vitro synthesis: uniqueness of adenine nucleotides. Biochem 1983; 22: 4518-26
46. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in p53 tumor suppression gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78
47. Monti P, Inga A, Aprile A, et al. p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients. Mutagenesis 2000; 15: 127-32
48. Peritz A, Douglass MC, McNiff J, et al. Analysis of p53 mutations based on microdissection of tumor bioipsies from psoriasis patients treated with PUVA. Photochem Photobiol 1999; 70: 29s-30s
49. Kripke ML. Effects of methoxsalen plus near-ultraviolet radiation or mid-ultraviolet radiation on immunologic mechanisms. Natl Cancer Inst Monogr 1984; 66: 247-51
50. Kumar JR, Haberman HF, Ranadive NS. Comparative studies on the tolerance to photoinduced cutaneous inflammatory reactions by psoralen and rose bengal. J Photochem Photobiol B 1997; 37: 245-53
51. Miller RA. Gerontology as oncology. Research on aging as the key to the understanding of cancer. Cancer 1991; 68 Suppl. 11: 2496-501
52. Gasparro FP. Extracorporeal photochemotherapy: clinical aspects and the molecular basis for efficacy. RG Landes Co, Medical Intelligence Unit, 1994
53. Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol Stockholm 1976; 56: 383-90
54. Bolognia JL, Freije L, Amici L, et al. Rectal suppositories of 8-methoxypsoralen produce ewer gastrointestinal side effects than the oral formulation. J Am Acad Dermatol 1996; 35: 424-7
55. Stolk L, Siddiqui AH, Kammeyer A, et al. Serum and saliva levels of 8-methoxypsoralen after rectal administration as a micro-enema. Br J Dermatol 1981; 104: 447-51
56. Billard V, Gambus PL, Baar J, et al. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans. Br J Clin Pharmacol 1995; 40: 347-60
57. Knobler RM, Trautinger F, Graninger W, et al. Parenteral administration of 8-methoxypsoralen in photopheresis. J Am Acad Dermatol 1993; 28: 580-4
58. Bachynsky MO, Infeld MH, Margolic RL, et al. Psoralen formulation for UV-A photopheresis. Eur Pat Appl EP 392, 429; US Appl 336, 179, 1990
59. Neild VS, Scott LV. Plasma levels of 8-methoxypsoralen in psoriatic patients receiving topical 8-methoxypsoralen. Br J Dermatol 1982; 106: 199-203
60. Pham CT, Koo JY. Plasma levels of 8-methoxypsoralen after topical paint PUVA. J Am Acad Dermatol 1993; 28: 460-6
61. Cristofolini M, Recchia G, Boi S, et al. 6-Methylangelicins: new monofunctional photochemotherapeutic agents for psoriasis. Br J Dermatol 1990; 122: 513-24
62. Tanew A. Half-side comparison of erythemogenic versus suberythemogenic UVA doses in oral photochemotherapy of psoriasis. J Am Acad Dermatol 1999; 41: 408-13
63. Ortel B, Perl S, Kinaciyan T, et al. Comparison of narrow-band (311 nm) UVB and broad-band UVA after oral or bath-water 8-methoxypsoralen in the treatment of psoriasis. J Am Acad Dermatol 1993; 29: 736-40
64. Filipe P, Emerit I, Youssefl AA, et al. Oxyradical-mediated clastogenic plasma factors in psoriasis. Increases in clastogenic activity after PUVA. Photochem Photobiol 1997; 66: 497-501
65. Taylor CR, Kwangsukstith C, Wimberly J, et al. Turbo-PUVA: dihydroxyacetone-enhanced photochemotherapy for psoriasis: a pilot study. Arch Dermatol 1999; 135: 540-4
66. Streit V, Wiedow O, Christophers E. Treatment of psoriasis with polyethylene sheet bath PUVA. J Am Acad Dermatol 1996; 35: 208-10
67. Murphy GM. Skin cancer in patients with psoriasis-many intertwined risk factors. Br J Dermatol 1999; 141: 1001-2
68. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42: 796-802